CELSION CORP (CLSN) Stock Price & Overview
NASDAQ:CLSN • US15117N6022
Current stock price
The current stock price of CLSN is 1.96 USD. Today CLSN is down by 0%. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.
CLSN Key Statistics
- Market Cap
- 13.914M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.21
- Dividend Yield
- N/A
CLSN Stock Performance
CLSN Stock Chart
CLSN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CLSN. When comparing the yearly performance of all stocks, CLSN is a bad performer in the overall market: 85.28% of all stocks are doing better.
CLSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSN. Both the profitability and financial health of CLSN have multiple concerns.
CLSN Earnings
CLSN Forecast & Estimates
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.
CLSN Groups
Sector & Classification
CLSN Financial Highlights
Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5229.82% | ||
| ROA | -40.03% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
CLSN Ownership
CLSN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLSN
Company Profile
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Company Info
IPO: 1993-10-27
CELSION CORP
997 Lenox Dr Ste 100
Lawrence Township NEW JERSEY 08648 US
CEO: Michael H. Tardugno
Employees: 29
Phone: 16098969100.0
CELSION CORP / CLSN FAQ
What does CLSN do?
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
What is the stock price of CELSION CORP today?
The current stock price of CLSN is 1.96 USD.
Does CELSION CORP pay dividends?
CLSN does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLSN stock?
CLSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for CLSN stock?
CELSION CORP (CLSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.21).
What is the employee count for CLSN stock?
CELSION CORP (CLSN) currently has 29 employees.
When does CELSION CORP (CLSN) report earnings?
CELSION CORP (CLSN) will report earnings on 2022-11-14.